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Four peptides were synthesized using solid phase peptide synthesis. The two target peptides 
synthesized were based off peptide 18-4 and its negative analog. Each were synthesized once manually, 
and once using an automatic peptide synthesizer. Peptide 18-4 has a high affinity for breast cancer cells, 
allowing it to be used to detect circulating tumor cells (CTCs) in blood (Kaur et. al, 2015). Manual solid 
phase peptide synthesis is performed by anchoring the first amino acid to Wang resin and coupling each 
Fmoc protected amino acid individually until the target sequence is achieved. To synthesize the peptides 
automatically, the automated Tribute Synthesizer was used. To analyze the success of the peptide 
synthesis, mass spectrometry was used to determine if the synthesized peptide has the correct molecular 
mass. Reversed Phase-High Performance Liquid Chromatography (RP-HPLC) was used to analyze the 
relative amount of the correct peptide in the synthesized sample. Due to greater potential for human error, 
the two peptides synthesized manually were missing one or two amino acids. Using the Tribute synthesizer, 
peptide 18-4 and its negative analog were successfully synthesized. Automated peptide synthesis was 
found to be faster and more successful than manual peptide synthesis.
Manual Solid Phase Synthesis:  Peptides 1 and 2 were synthesized manually.  The 1st amino acid 
activated using Oxyma and DIC, was coupled to Wang resin. The amino acid bound to resin was 
deprotected from Fmoc using 20% piperidine. The 2nd amino acid activated by dissolving in DMF with 
HCTU and NMM, was then added to the resin bound 1st amino acid for coupling. The peptide was 
elongated by repeating the deprotection and coupling steps until the peptide was complete. Complete 
peptide was cleaved from the resin and purified. 
Synthesis Using Tribute Synthesizer:  Peptides 3 and 4 were synthesized using the Tribute Synthesizer. 
Each amino acid was added to a separate labeled tube with HTCU. Each tube was loaded into the Tribute 
Synthesizer and left to synthesize overnight. The peptide was then cleaved and purified as above. 
MALDI-TOF and RP-HPLC of Peptide Samples:  The calculated molecular weight of the peptide was 
found using the website pepcalc.com. After cleavage, the sample was mixed with MALDI matrix and then 
spotted onto the MALDI plate. The plate was inserted into the MALDI-TOF and, using the computer 
program provided, an appropriate mass range was selected for analysis. 
For RP-HPLC of Peptides 3 and 4, 100-500 µL of peptide solution (in DMF and water) was injected.  
Each large peak, apart from the very first and very last was collected in a separate tube. Each peak was 
analyzed using MALDI-TOF to determine the peak that corresponds to pure peptide. 
The goal of this research was to successfully synthesize two peptides, peptide 18-4 (NH2 -
WxEAAYQrFLC - COOH) and its negative analog (NH2 - WxEAAYQrFLC - COOH ). The peptides 
synthesized are intended for use in real-time detection of breast cancer cells. Peptide 18-4 has high affinity 
for breast cancer cells, and can thus be used with a microcantilever array system to selectively detect 
circulating tumor cells in blood. This peptide was discovered by Kaur and her research team at the 
University of Alberta (Kaur et. al, 2015).
To synthesize a peptide using solid-phase synthesis, the C terminal amino acid is bound to resin and 
then each successive amino acid is coupled to the N-terminus. In solid phase synthesis, the basic 
procedure is as follows:
1. Coupling of the first amino acid to resin
2. Deprotection of the first amino acid
3. Activation and coupling of next amino acid
4. Elongation of the peptide (deprotection, activation, coupling)
5. Cleavage of the peptide from the resin
To analyze whether or not the correct amino acids are present in a peptide during or after synthesis, 
mass spectrometry is used. The mass ([M+H]+1) of the cleaved peptide is determined using Matrix-Assisted 
Laser Desorption/ionization - Time of Flight (MALDI-TOF) mass spectrometry. To determine the relative 
amount of the target peptide in a sample or purity of the sample, reversed-phase high performance liquid 
chromatography (RP-HPLC) is used. Table 1 outlines the four peptides synthesized.
Peptide 1
• Peptide 1 has two found molecular weights, 
which indicates that Peptide 1 consists of two 
peptides: one missing glutamate and alanine, 
and the other missing alanine from the target 
sequence. 
• Peptide 1 will not be sufficient at binding to 
CTC’s, so manual synthesis of Peptide 18-4 was 
unsuccessful.
Peptide 2
• Peptide 2 is missing the amino acid threonine. 
Peptide 3
• Peptide 3 was successfully synthesized and 
should be able to selectively bind to CTC’s. 
• The RP-HPLC of Peptide 3 indicates that a clean, 
mostly pure peptide is present.
Peptide 4
• Synthesis of Peptide 4 was at first unsuccessful, 
but after manually coupling norleucine, it can be 
used as a negative analog of Peptide 4. 
• The HPLC of Peptide 4 coupled to norleucine
indicates three peptides are present. 
• Because Peptide 4 is to be used as a negative 
analog, the presence of two minor peptides will 
not interfere with future work. 
In conclusion, manual synthesis was unsuccessful 
at synthesizing Peptides 1 and 2. Automated 
synthesis was successful at synthesizing Peptides 3 
and 4 to be used as Peptide 18-4 and its negative 
analog. These peptides are to be used in future 
research involving selective binding to CTC’s. 
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Figure 1. Mass Spec of Peptide 1
The mass [M+H]+1 calculated was 
1296 Da and the masses found were 
1036 Da and 1183 Da.
Figure 2. Mass Spec of Peptide 2
The mass calculated was 1082 Da 
and the mass found was 981.46 Da.
Figure 3. Mass Spec of Peptide 3
The mass calculated was 1296 Da 
and the mass found was 1296 Da.
Figure 4. Mass Spec of Peptide 4 
with norleucine coupled
The mass calculated was 1094 Da 
and three masses were found. The 
major peak shows a mass of 1095 
Da. The minor peaks show masses 
of 967 Da, 932 Da and 1024 Da. 
Figure 5. RP-HPLC of Peptide
The peak that eluted at 51 minutes contained a peptide with a found 
mass of 1296 Da, indicating presence of Peptide 3. 
Figure 6. RP-HPLC of Peptide 4 with norleucine manually coupled. 
Three major peaks eluted, one at 31 minutes, 40 minutes, and 42 minutes. The 31-
minute peak contained a peptide with a mass of 947 Da and the 42-minute peak 
contained a peptide with a mass of 967 Da. The 40-minute elution peak contained a 
peptide with the mass of 1095 Da, indicating the presence of Peptide 4 with norleucine
coupled. 
Table 2. Summary of Peptides Synthesized
Peptide Name Target Sequence Calculated 
Molecular Weight
Found
Molecular Weight
Found Sequence
Peptide 1 NH2 - WxEAAYQrFL - COOH 1296 Da a. 1036 Da
b. 1183 Da 
a. NH2 - WxAYQrFL - COOH [M + Na]
b. NH2 - WxEAYQrFL - COOH [M + Na]
Peptide 2 NH2 - EPAAYQRFT - COOH 1082 Da 981.46 Da NH2 - EPAAYQRF - COOH
Peptide 3 NH2 - WxEAAYQrFLC - COOH 1296 Da 1296 Da NH2- WxEAAYQrFLC - COOH
Peptide 4 
w/ norleucine
NH2 - xEPAAYQRF - COOH 1094 Da Major: 1095 Da
Minor A: 947
Minor B: 967 Da
Major Pep: NH2 - xEPAAYQRF - COOH
Minor A: NH2 - xEPAAYQR - COOH
Minor B: NH2 - xEPAAYRF - COOH
Table 1. Description of Peptides Synthesized
Peptide Method of Synthesis Target Sequence Calculated 
Molecular Weight 
Peptide 1 Manual Synthesis by Alicia Cuber NH2 - WxEAAYQrFL - COOH 1296 Da
Peptide 2 Manual Synthesis NH2 - EPAAYQRFT - COOH 1082 Da
Peptide 3 Tribute Automatic Synthesizer NH2 - WxEAAYQrFL - COOH 1296 Da
Peptide 4 Tribute Automatic Synthesizer NH2 - EPAAYQRFT - COOH 1082 Da
